Predictive Oncology INC Form 4 insider transactions

Predictive Oncology's Interim CFO, Joshua Blacher, was granted 97,000 restricted stock units, which are scheduled to vest on October 31, 2025.

Predictive Oncology Inc.'s CEO, Raymond F. Vennare, was granted 124,959 restricted stock units, vesting fully on October 31, 2025.

Predictive Oncology and Renovaro extend their merger agreement termination date to March 31, 2025, with Renovaro providing initial financing to integrate AI/ML platforms and expand business development.

Gregory St. Clair Sr., a director of Predictive Oncology Inc., acquired 3,268 shares of common stock on April 5, 2024.

Director Matthew Hawryluk of Predictive Oncology Inc. reports acquiring and disposing of common stock on April 5, 2024.

Director Veena Rao of Predictive Oncology Inc. reports acquiring and disposing of common stock on April 5, 2024.

Director Charles Lee Nuzum Sr. reports acquiring 3,268 shares of Predictive Oncology Inc. common stock on April 5, 2024.

Director Daniel E. Handley reports acquiring and disposing of shares of Predictive Oncology Inc. on April 5, 2024.

Director Nancy Chung-Welch reports acquiring and disposing of Predictive Oncology Inc. (POAI) common stock on April 5, 2024.